FDA expands use of endovascular graft to treat aortic tears
FDA expands use of endovascular graft to treat aortic tears
The U.S. Food and Drug Administration today expanded the approved usage for an endovascular graft manufactured by W.L. Gore and Associates Inc. to include treatment of life-threatening tears or ruptures of the aorta (thoracic aortic transection). (MB)